Mandate Vinge advises Oncopeptides in connection with a directed share issue

June 28, 2019

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 727 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank AB (publ), Cowen, DNB Markets, a part of DNB Bank ASA, Jefferies International Limited and Kempen & CO N.V.

Oncopeptides is a clinical development pharmaceutical company focused on conducting anti-cancer research to develop treatments for the benefit of patients. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun and Hampus Olsson.

Insurance law and blockage of the Suez Canal

One of the largest container ships in the world is still blocking the Suez Canal, an event which can have significant global consequences. Even Swedish interested parties such as the Port of Gothenburg may also be affected by the situation. The running aground is a clear reminder of the vulnerability of global transport chains, and sheds light on a number of important insurance issues.
March 29, 2021

Vinge top-ranked by Chambers & Partners within ten practice areas

Vinge would like to thank all the clients who have contributed with their time through the interview processes for Chambers’ annual rankings. We have today received the result, and we are delighted with top rankings in 13 areas and a significant number of individual rankings.
March 19, 2021

Vinge’s Managing Partner Maria-Pia Hope is chosen as one of the most powerful women in Swedish business by Dagens Industri

Maria Pia Hope, Managing Partner at Vinge, stands out as one of the few lawyers on the list when Dagens Industri presents its list of the most powerful women in business.
March 08, 2021